Halofuginone inhibition of COL1A2 promoter activity via a c-Jun-dependent mechanism

Tracy L. McGaha, Takao Kodera, Harry Spiera, Alexandru C. Stan, Mark Pines, Constantin A. Bona

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Objective. The naturally occurring compound halofuginone has been shown to antagonize collagen synthesis by fibroblasts both in vitro and in vivo. We previously demonstrated that this inhibitory property was related to the ability of halofuginone to disrupt transforming growth factor β signal transduction. The present study further analyzed the ability of halofuginone to affect transcription factors that can regulate type I collagen gene expression by examining its effect on c-Jun, the negative regulator of collagen gene transcription. Methods. The phosphorylation state of c-Jun in the presence of halofuginone was examined via direct Western blotting, and the transcriptional activity of the activator protein 1 (AP-1) binding element via electrophoretic mobility shift assay and luciferase reporter assay. We determined whether the effect of halofuginone on collagen synthesis was dependent on the presence of c-Jun by ectopic expression of a wild-type or dominant-negative c-Jun construct in the presence of halofuginone and assaying α2(I) collagen promoter strength via luciferase reporter assay. The effect of halofuginone on α2(I) collagen message levels in fibroblasts when wild-type or dominant-negative c-Jun was overexpressed was determined. We also determined whether halofuginone had an effect on the phosphorylation state of c-Jun in the skin of TSK/+ mice via immunohistochemistry. Results. Treatment of fibroblasts with 10-8M halofuginone enhanced basal and mitogen-mediated phosphorylation of c-Jun in culture. This elevated phosphorylation of c-Jun correlated with enhanced DNA binding and transcriptional activation of an AP-1 complex consisting of c-Jun and Fos but lacking the c-Jun antagonist JunB. Overexpression of c-Jun enhanced in a dose-dependent manner the ability of halofuginone to inhibit the activity of a luciferase reporter construct under control of the -3200-bp to +54-bp COL1A2 promoter, whereas the expression of a dominant-negative c-Jun construct abolished this effect. Northern blotting showed that overexpression of c-Jun enhanced the ability of halofuginone to reduce collagen α2(I) messenger RNA levels in fibroblasts, whereas expression of the dominant-negative c-Jun abolished this effect. Topical administration of a halofuginone-containing cream for 20 days to TSK mice, which spontaneously develop dermal fibrosis, greatly increased the phosphorylated form of c-Jun in the skin; this was followed by a decrease in skin thickness and type I collagen messenger RNA expression. Conclusion. Our findings illustrate the powerful down-regulatory property of c-Jun toward type I collagen and establish that halofuginone exerts its effect on collagen synthesis in a c-Jun-dependent manner.

Original languageEnglish (US)
Pages (from-to)2748-2761
Number of pages14
JournalArthritis and Rheumatism
Volume46
Issue number10
DOIs
StatePublished - Oct 1 2002

Fingerprint

Collagen
Fibroblasts
Collagen Type I
Luciferases
Phosphorylation
Skin
Transcription Factor AP-1
halofuginone
alpha 2(I) collagen
Topical Administration
Messenger RNA
Transforming Growth Factors
Electrophoretic Mobility Shift Assay
Regulator Genes
Mitogens
Protein Binding
Northern Blotting
Transcriptional Activation
Signal Transduction
Fibrosis

ASJC Scopus subject areas

  • Immunology
  • Rheumatology

Cite this

McGaha, T. L., Kodera, T., Spiera, H., Stan, A. C., Pines, M., & Bona, C. A. (2002). Halofuginone inhibition of COL1A2 promoter activity via a c-Jun-dependent mechanism. Arthritis and Rheumatism, 46(10), 2748-2761. https://doi.org/10.1002/art.10549

Halofuginone inhibition of COL1A2 promoter activity via a c-Jun-dependent mechanism. / McGaha, Tracy L.; Kodera, Takao; Spiera, Harry; Stan, Alexandru C.; Pines, Mark; Bona, Constantin A.

In: Arthritis and Rheumatism, Vol. 46, No. 10, 01.10.2002, p. 2748-2761.

Research output: Contribution to journalArticle

McGaha, TL, Kodera, T, Spiera, H, Stan, AC, Pines, M & Bona, CA 2002, 'Halofuginone inhibition of COL1A2 promoter activity via a c-Jun-dependent mechanism', Arthritis and Rheumatism, vol. 46, no. 10, pp. 2748-2761. https://doi.org/10.1002/art.10549
McGaha, Tracy L. ; Kodera, Takao ; Spiera, Harry ; Stan, Alexandru C. ; Pines, Mark ; Bona, Constantin A. / Halofuginone inhibition of COL1A2 promoter activity via a c-Jun-dependent mechanism. In: Arthritis and Rheumatism. 2002 ; Vol. 46, No. 10. pp. 2748-2761.
@article{2a50afe3a2ec4e35a9e7aeb613ff27e3,
title = "Halofuginone inhibition of COL1A2 promoter activity via a c-Jun-dependent mechanism",
abstract = "Objective. The naturally occurring compound halofuginone has been shown to antagonize collagen synthesis by fibroblasts both in vitro and in vivo. We previously demonstrated that this inhibitory property was related to the ability of halofuginone to disrupt transforming growth factor β signal transduction. The present study further analyzed the ability of halofuginone to affect transcription factors that can regulate type I collagen gene expression by examining its effect on c-Jun, the negative regulator of collagen gene transcription. Methods. The phosphorylation state of c-Jun in the presence of halofuginone was examined via direct Western blotting, and the transcriptional activity of the activator protein 1 (AP-1) binding element via electrophoretic mobility shift assay and luciferase reporter assay. We determined whether the effect of halofuginone on collagen synthesis was dependent on the presence of c-Jun by ectopic expression of a wild-type or dominant-negative c-Jun construct in the presence of halofuginone and assaying α2(I) collagen promoter strength via luciferase reporter assay. The effect of halofuginone on α2(I) collagen message levels in fibroblasts when wild-type or dominant-negative c-Jun was overexpressed was determined. We also determined whether halofuginone had an effect on the phosphorylation state of c-Jun in the skin of TSK/+ mice via immunohistochemistry. Results. Treatment of fibroblasts with 10-8M halofuginone enhanced basal and mitogen-mediated phosphorylation of c-Jun in culture. This elevated phosphorylation of c-Jun correlated with enhanced DNA binding and transcriptional activation of an AP-1 complex consisting of c-Jun and Fos but lacking the c-Jun antagonist JunB. Overexpression of c-Jun enhanced in a dose-dependent manner the ability of halofuginone to inhibit the activity of a luciferase reporter construct under control of the -3200-bp to +54-bp COL1A2 promoter, whereas the expression of a dominant-negative c-Jun construct abolished this effect. Northern blotting showed that overexpression of c-Jun enhanced the ability of halofuginone to reduce collagen α2(I) messenger RNA levels in fibroblasts, whereas expression of the dominant-negative c-Jun abolished this effect. Topical administration of a halofuginone-containing cream for 20 days to TSK mice, which spontaneously develop dermal fibrosis, greatly increased the phosphorylated form of c-Jun in the skin; this was followed by a decrease in skin thickness and type I collagen messenger RNA expression. Conclusion. Our findings illustrate the powerful down-regulatory property of c-Jun toward type I collagen and establish that halofuginone exerts its effect on collagen synthesis in a c-Jun-dependent manner.",
author = "McGaha, {Tracy L.} and Takao Kodera and Harry Spiera and Stan, {Alexandru C.} and Mark Pines and Bona, {Constantin A.}",
year = "2002",
month = "10",
day = "1",
doi = "10.1002/art.10549",
language = "English (US)",
volume = "46",
pages = "2748--2761",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "10",

}

TY - JOUR

T1 - Halofuginone inhibition of COL1A2 promoter activity via a c-Jun-dependent mechanism

AU - McGaha, Tracy L.

AU - Kodera, Takao

AU - Spiera, Harry

AU - Stan, Alexandru C.

AU - Pines, Mark

AU - Bona, Constantin A.

PY - 2002/10/1

Y1 - 2002/10/1

N2 - Objective. The naturally occurring compound halofuginone has been shown to antagonize collagen synthesis by fibroblasts both in vitro and in vivo. We previously demonstrated that this inhibitory property was related to the ability of halofuginone to disrupt transforming growth factor β signal transduction. The present study further analyzed the ability of halofuginone to affect transcription factors that can regulate type I collagen gene expression by examining its effect on c-Jun, the negative regulator of collagen gene transcription. Methods. The phosphorylation state of c-Jun in the presence of halofuginone was examined via direct Western blotting, and the transcriptional activity of the activator protein 1 (AP-1) binding element via electrophoretic mobility shift assay and luciferase reporter assay. We determined whether the effect of halofuginone on collagen synthesis was dependent on the presence of c-Jun by ectopic expression of a wild-type or dominant-negative c-Jun construct in the presence of halofuginone and assaying α2(I) collagen promoter strength via luciferase reporter assay. The effect of halofuginone on α2(I) collagen message levels in fibroblasts when wild-type or dominant-negative c-Jun was overexpressed was determined. We also determined whether halofuginone had an effect on the phosphorylation state of c-Jun in the skin of TSK/+ mice via immunohistochemistry. Results. Treatment of fibroblasts with 10-8M halofuginone enhanced basal and mitogen-mediated phosphorylation of c-Jun in culture. This elevated phosphorylation of c-Jun correlated with enhanced DNA binding and transcriptional activation of an AP-1 complex consisting of c-Jun and Fos but lacking the c-Jun antagonist JunB. Overexpression of c-Jun enhanced in a dose-dependent manner the ability of halofuginone to inhibit the activity of a luciferase reporter construct under control of the -3200-bp to +54-bp COL1A2 promoter, whereas the expression of a dominant-negative c-Jun construct abolished this effect. Northern blotting showed that overexpression of c-Jun enhanced the ability of halofuginone to reduce collagen α2(I) messenger RNA levels in fibroblasts, whereas expression of the dominant-negative c-Jun abolished this effect. Topical administration of a halofuginone-containing cream for 20 days to TSK mice, which spontaneously develop dermal fibrosis, greatly increased the phosphorylated form of c-Jun in the skin; this was followed by a decrease in skin thickness and type I collagen messenger RNA expression. Conclusion. Our findings illustrate the powerful down-regulatory property of c-Jun toward type I collagen and establish that halofuginone exerts its effect on collagen synthesis in a c-Jun-dependent manner.

AB - Objective. The naturally occurring compound halofuginone has been shown to antagonize collagen synthesis by fibroblasts both in vitro and in vivo. We previously demonstrated that this inhibitory property was related to the ability of halofuginone to disrupt transforming growth factor β signal transduction. The present study further analyzed the ability of halofuginone to affect transcription factors that can regulate type I collagen gene expression by examining its effect on c-Jun, the negative regulator of collagen gene transcription. Methods. The phosphorylation state of c-Jun in the presence of halofuginone was examined via direct Western blotting, and the transcriptional activity of the activator protein 1 (AP-1) binding element via electrophoretic mobility shift assay and luciferase reporter assay. We determined whether the effect of halofuginone on collagen synthesis was dependent on the presence of c-Jun by ectopic expression of a wild-type or dominant-negative c-Jun construct in the presence of halofuginone and assaying α2(I) collagen promoter strength via luciferase reporter assay. The effect of halofuginone on α2(I) collagen message levels in fibroblasts when wild-type or dominant-negative c-Jun was overexpressed was determined. We also determined whether halofuginone had an effect on the phosphorylation state of c-Jun in the skin of TSK/+ mice via immunohistochemistry. Results. Treatment of fibroblasts with 10-8M halofuginone enhanced basal and mitogen-mediated phosphorylation of c-Jun in culture. This elevated phosphorylation of c-Jun correlated with enhanced DNA binding and transcriptional activation of an AP-1 complex consisting of c-Jun and Fos but lacking the c-Jun antagonist JunB. Overexpression of c-Jun enhanced in a dose-dependent manner the ability of halofuginone to inhibit the activity of a luciferase reporter construct under control of the -3200-bp to +54-bp COL1A2 promoter, whereas the expression of a dominant-negative c-Jun construct abolished this effect. Northern blotting showed that overexpression of c-Jun enhanced the ability of halofuginone to reduce collagen α2(I) messenger RNA levels in fibroblasts, whereas expression of the dominant-negative c-Jun abolished this effect. Topical administration of a halofuginone-containing cream for 20 days to TSK mice, which spontaneously develop dermal fibrosis, greatly increased the phosphorylated form of c-Jun in the skin; this was followed by a decrease in skin thickness and type I collagen messenger RNA expression. Conclusion. Our findings illustrate the powerful down-regulatory property of c-Jun toward type I collagen and establish that halofuginone exerts its effect on collagen synthesis in a c-Jun-dependent manner.

UR - http://www.scopus.com/inward/record.url?scp=0036822655&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036822655&partnerID=8YFLogxK

U2 - 10.1002/art.10549

DO - 10.1002/art.10549

M3 - Article

C2 - 12384935

AN - SCOPUS:0036822655

VL - 46

SP - 2748

EP - 2761

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 10

ER -